Dr. Dennis L. Ross, MD, FACP, FASN

Areas of expertise and specialization

Faculty Titles & Positions

• Local, Regional, and National Public Speaking for Academic, Continued Medical Education, and Some Work with Pharmaceutical Companies -
• Clinical Professor at the University of Kansas Medical School -
• CEO Wichita Grand Opera -

Awards

• Recognized by the Wichita Business Journal-Health Heroes 2012   
• Recipient of the Kansas Governors Award for the Arts   
• Health Hero 2012 Wichita Business Journa 
• Kansas Governor's Award for the Arts Year  

Treatments

• Anemia
• Osteoporosis
• Chronic Kidney Disease
• Vascular Disease

Professional Memberships

• Fellow of both the American College of Physicians (FACP)  
• American Society of Nephrology (FASN)  
• American Society of Interventional Nephrology  
• Renal Physicians Association  
• American Association of Research Professionals  

Fellowships

• Jewish Hospital  

Charities and Philanthropic Endeavors

• Wichita Grand Opera
• Wichita Symphony, Wichita Kansas
• Music Theater of Wichita
• Lutheran Hour Ministries
• Concordia University, Seward Nebraska
• University of Nebraska Medical Center
• Concordia Theological Seminary, Fort Wayne Indiana
• Exploration Place, Wichita Kansas

Internships

• Wesley Medical Center, Wichita Kansas

Fellowships

• Jewish Hospital St. Louis Missour

Professional Society Memberships

• American Society of NephrologyAmerican Society of Interventional NephrologyRanal Physicians AssociationAmerican Association of Research Professionals

Articles and Publications

• Publications:1.Ross, D.L. and Weber, H. Hypertension and the Nail-Patella Syndrome, J. Kansas Med. Soc., pp. 268-270, Nov 19752.Ross, D.L. and Weber, H. Bartters Syndrome A Metabolic Study, J. Kansas Med. Soc., pp. 378-382, Sept. 19763.Ross, D.L. and Drevets, C. Nitrofurantoin-Induced Lung Disease, J. Kansas Med. Soc., pp. 163165, July 19754.Ross, D.L., Pina, J., Ponce, L., and Mirza, M. Regression of the Focal Nodular Hyperplasia and Discontinuation of Oral Contraceptives: Annals of Int. Med. 85: (2), 203-204, Aug. 1976.5.Ross, D.L. and Lubowitz, H. Longterm Anticoagulaiton in Renal Vein Thrombosis, Archives Int. Med., pp. 1349-1351, Sept. 19786.Jawadi, M.J., Ho, L.S., Dipette, D., and Ross, D.L. Regulation of Plasma Arginine Vasopressin in Patients with Chronic Renal Failure Maintained on Hemodialysis, American Journal of Nephrology, pp. 175-181, June.7.A. Felsenfeld, M. Rodriguez, M. Coleman, D. Ross, and F. Llach. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease, Kidney International, Vol. 35 (1989), pp. 1371-1378.8.Ross, D., Grabau, g., Smith, S., Seymour, M., Knierim, N. Efficiency of Exercise of End-Stage Renal Disease Patients Immediately following High-Efficiency Hemodialysis: A Pilot Study, American Journal of Nephrology, 1989, 9:376-383.9.A.J. Felsenfeld, D.L. Ross, K.D. Campbell, D.K. Wimberley, G. Vasudevan. Hysteresis of the Parathyroid Hormone Response to Hypocalcemia in Hemodialysis Patients with Low Turnover Aluminum Bone Disease, JASN, Vol. 2, Nov. 6, 1991.10.K.H. Pitteti, D.L. Ross, K.D. Campbell, D.K. Wimberley, G. Vasudevan. Exercise Capacity of Hemodialysis Patients Following Recombinant Human Erythropoietin Treatment: Sports Medicine, Training and Rehabilitation, Vol. 3, No. 1, October 1991.11.Dennis L. Ross, Wendy Funk Schrag, Paula Pond (2016). Dialysis in Older Adults. In Madhukr Misra (Ed.), The Pros and Cons of Home vs In-center Dialysis in the Elderly (pp 29-44), New York, New York: Springer.Abstracts:1. Ross, D.L., Mazumdar, D.C., Meyer, K.S. and Lubowitz, H. Is Exercise Harmful in Glomerulonephritis? A Study in the Rat Abstract, Am. Fed. Clin. Res., 19772.Fernandes, J., Ross, D., Mazumdar, D.C. and Lubowitz, H. Sodium Excretion in Uremia: The Role of Dietary Salt Abstract, VIIth International Congress of Nephrology, Montreal, 19783.Wolf, P., Ross, D., Bruner, K. Plasmapheresis in the Treatment of Cryoglobulinemia Abstract, Kansas Reg. Meeting, A. Col. Phys., February 1980.4.Webb, D., Peterie, J., Herschberger, R., Ross, D.L., Toxic Shock Syndrome with Severe Multi-System Involvement Abstract, Kansas Reg. Meeting, Am. Col. Phys., February 1981.5.Saunders, M. and Ross, D.L. Rapidly Progressive Glomerulonephritis: A Favorable Response to Pulse Corticosteroid Therapy Abstract, Kansas Reg. Mtg., Am. Col. Phys., March 1983.6.Classen, L. and Ross, D.L. Prediction of Creatinine in Chronic Renal Disease Abstract, Kansas Reg. Mtg., Am Col. Phys., March 19827.Wells, B., Ross, D.L., Galichia, J. and Shield, C. Transluminal Angioplasty in the Treatment of Transplanted Kidney Renal Artery Stenosis Abstract, Kansas Reg. Mtg., Am. Col. Phys., March 1983.8.Finney, M., Dolan, P., Ross, D.L., and Skibba, R., Calcitonin Secreting Hepatocellular Carcinoma A Case Report Abstract, Kansas Reg., Mtg., Am. Col. Of Phys., March 1984.9.Stephanz, G. Goodpasture, H., Knierim, . and Ross, D. Peritoneal Catheter Removal in Patients on A.A.P.D. Abstract, Third International Symposium on Peritoneal Dialysis, Washington, D.C., June 1984.10.Stephanz, G. and Ross, D.L. Antibody Response to Hepatitis B Vaccine in Dialysis Patients Abstract, Kansas Reg., Mtg. Am. Col. Of Phys., March 1985.11.Bergh, James and Ross, Dennis. Single Photon Absorptiometry and Correlation with Age, Screening Questionnaire Risk and Prior Bone Fractures Abstract, Kansas Reg. Mtg., Am. Col. Of Phys., September 198612.Gordon, R., Keim, R., Ross, D.,, and Hoffman, J. Elevated Levels of Calcitonin with Evidence of Increased Bone Density in a Patient with a Gluycagonoma Abstract, Kansas Reg. Mtg., Am Col. Of Phys., September 1986.13.Ahlstorm, N., Bergh, J., Francisco., L., Ross, D., Webre, H., Cohlmia, J., Day, H., and Meredith, W.T. Results of a Clinical Trial of High Efficiency Hemodialysis in 43 Patients Abstract, Kansas Reg. Mtg., Am. Col. Of Phys., September 1987.14.A. Felsenfeld, M. Rodriquez, M. Coleman, D. Ross, and F. Llach. The Effect of Desferrioxamine (DFO) on Aluminum Bone Disease and Parathyroid Hormone, (PTH) Abstract, American Society of Nephrology, December 1987.15.Ross, D.L., Grabau, G., Smith, S., Seymour, M., Knierim, N. The Efficiency of Exercise for End-Stage Renal Disease Patients Immediately Following High Efficiency Hemodialysis; A Pilot Study Poster, National ACP Meeting, April 1989, San Francisco, California.16.Janssen J. Williams and Dennis L. Ross Resolution Intra-Cranial MRI Abnormals after Hypertension Correction Abstract, American College of Physicians, August 1992.Posters:1.The Effect of a Low Calcium Dialysate on the PTH Secretion in Diabetic Patients on Maintenance Hemodialysis; Roberto Holgado, Henry Haire, Dennis Ross, Stuart Sprague, Madeleine Pahl, Aquiles Jara, Alejandro Martin-Malo, Mariano Rodriguez, Yolanda Almaden, and Arnold J. Felsenfeld. Presented at the ASN meeting, San Antonia, Texas, October 1998.2.PIXI Bone Density Screening for Osteoporosis; Dennis L. Ross, M.D., Jens Borg, Ph.D., James Simon, M.D. Presented at American Society of Bone and Mineral Metabolism Meeting, San Francisco, California, December 1998.Research Activities:Bayer Protocol 21177A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.Principal InvestigatorBayer Protocol 20103A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction 40% (LVEF 40%).Sub-InvestigatorAstraZeneca D4325C00001A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) 20 mL/min/1.73 m2.Principal InvestigatorAstraZeneca D1690C00078A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure.Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)Sub-InvestigatorAstraZeneca D8850C00002 PROVENTA Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19Principal InvestigatorResearch Activities (cont.): AstraZeneca D9183C00001- FRONTIERA Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease.Principal InvestigatorArdelyx TEN-02-301 PHREEDOMA 26 week, Phase 3, open label study with an up to 12-week, placebo-controlled, randomized withdrawal period followed by an up to 26-week open label long term safety extension to evaluate the safety and efficacy of Tenapanor to treat hyperphosphatemia in end-stage renal disease patients on hemodialysis and peritoneal dialysis.Principal InvestigatorGilead GS-US-223-1017A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease.Principal InvestigatorReata Pharmaceuticals FALCON 402-C-1808 A Phase III Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease.Principal InvestigatorIronwood EXPLORE Protocol RDEA594-401A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared with an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance 20 to

What do you attribute your success to?

• I grew up in a small town in Nebraska and was expected to work from a young age. This engendered a strong work ethic

Philanthropic Initiatives

• My wife and I have focused our charitable giving to our church, the arts, and the medical institution where we were trained.

Teaching and speaking

• I have published two Medical Thrillers:The Perfect MatchThe Lethal Elixir

Favorite Place to Vacation

• Los Cabos

Hobbies / Sports

• I play the saxaphone and piano and sing in the church choir.

Areas of research

Pharmaceutical Sponsored trials in Nephrology, General Internal Medicine, and Cardiology

Dr. Dennis L. Ross, MD, FACP, FASN's Practice location